Enters | PharmaShots

Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic

April 3, 2020April 3, 2020Tuba Khan

Shots: The transition to the second phase of development follows the completion of the first phase of securing 300 different types of Abs [Read More...]

Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets

March 6, 2020March 9, 2020Tuba Khan

Shots: Orionis to receive research funding, convertible notes, clinical milestones along with royalties while Novartis gets access to Orionis’ Allo-Glue technology platform for [Read More...]

MSD Signs a License Agreement with King’s College London & Wellcome’s Innovations to Develop Chronic Neuropathic Pain Therapies

MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications

September 24, 2019September 24, 2019Tuba Khan

Shots: MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate [Read More...]

Vertex Enters into an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)

Vertex Signs an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)

September 12, 2019September 12, 2019Tuba Khan

Shots: The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland Vertex [Read More...]

Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug Discovery

September 12, 2019September 12, 2019Tuba Khan

Shots: Atomwise to receive technology access fees, option exercise fees, royalties, and income-based on sublicensing or sale of assets leading to a total [Read More...]

Alexion Enters into an Exclusive License Agreement with Eidos to Develop and Commercialize AG10 in Japan

September 10, 2019September 10, 2019Tuba Khan

Shots: Eidos to receive $25M upfront, $25 equity investment at a premium to the market price upon deal execution, milestone and royalties. Alexion [Read More...]

Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway

September 5, 2019September 5, 2019Tuba Khan

Shots: Novartis to get an option to acquire IFM Due (a subsidiary of IFM Therapeutics) in exchange of funding for research & development [Read More...]

Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to Expand its KRAS Cancer Program

September 4, 2019September 4, 2019Tuba Khan

Shots: Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim [Read More...]

Celltrion and Teva’s Herzuma (trastuzumab-pkrb, Herceptin biosimilar) Receives FDA’s Approval for HER2-Overexpressing Breast Cancer

Celltrion Enters into a Contract to Manufacture Agreement for its Remsima (biosimilar, infliximab) with Lonza

September 4, 2019September 4, 2019Tuba Khan

Shots: Celltrion has picked to manufacture its biosimilar Remsima’s drug substance at Lonza’s Singapore facility to supply it in American and European markets [Read More...]

Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

September 3, 2019September 3, 2019Tuba Khan

Shots: Blanver to register, promote, distribute & commercialize Pracinostat in Brazil while Varifarma to get rights in Argentina, Bolivia, Chile, Colombia, Ecuador, Paraguay, [Read More...]